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Background: Chronic obstructive pulmonary disease (COPD) exacerbations are accompanied with increased
systemic inflammation, which accelerate the pulmonary function injury and impair the quality of life. Prompt and
effective treatments for COPD exacerbations slow down the disease progression, but an objective instrument to
assess the efficacy of the treatments following COPD exacerbations is lacking nowadays. The COPD Assessment Test
(CAT) is an 8-item questionnaire designed to assess and quantify health status and symptom burden in COPD
patients. We hypothesize that the change in CAT score is related to the treatment response following COPD
exacerbations.
Methods: 78 inpatients with clinician-diagnosed acute exacerbation of COPD (AECOPD) completed the CAT,
St George’s Respiratory Questionnaire (SGRQ) and modified Medical Research Council (mMRC) Dyspnea Scale both
at exacerbation and the 7th day of therapy, and a subgroup of 39 patients performed the pulmonary function test.
Concentrations of serum C-reactive protein (CRP) and plasma fibrinogen were assayed at the same time.
Correlations between the CAT and other measurements were examined.
Results: After 7 days’ therapy, the CAT and SGRQ scores, mMRC grades, as well as the concentrations of CRP and
fibrinogen all decreased significantly (P < 0.001). Meanwhile, the FEV1% predicted had a significant improvement
(P < 0.001). The CAT scores were significantly correlated with concurrent concentrations of CRP and fibrinogen,
SGRQ scores, FEV1% predicted and mMRC grades (P < 0.05). The change in CAT score was positively correlated
with the change of CRP (r = 0.286, P < 0.05), SGRQ score (r = 0.725, P < 0.001) and mMRC grades (r = 0.593, P < 0.001),
but not with fibrinogen (r = 0.137, P > 0.05) or FEV1% predicted (r = −0.101, P > 0.05). No relationship was found
between the changes of SGRQ score and CRP and fibrinogen (P>0.05).
Conclusions: The CAT is associate with the changes of systemic inflammation following COPD exacerbations.
Moreover, the CAT is responsive to the treatments, similar to other measures such as SGRQ, mMRC dyspnea scale
and pulmonary function. Therefore, the CAT is a potentially useful instrument to assess the efficacy of treatments
following COPD exacerbations.
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Chronic obstructive pulmonary disease (COPD) is a com-
mon chronic respiratory disease around the world and it
has become an increasing public health concern to the
Chinese medical community [1]. COPD is associated with
periodic exacerbations which manifest as worsening of
lung function and increased dyspnea, cough, and sputum
production [2,3]. COPD exacerbations cause hospital ad-
missions, morbidity and mortality, directly leading to the
deterioration of health-related quality of life [4]. It’s gene-
rally believed that exacerbations are important targets
for treatments and prevention of disease progression of
COPD [2]. Clinicians routinely use various methods to
assess the health status and response to treatments of
COPD patients [5], but a simple and objective instrument
to evaluate the treatments response following AECOPD is
still lacking currently.
The COPD Assessment Test (CAT) is a recently intro-
duced, patient-completed instrument to assess and quan-
tify health-related quality of life and symptom burden in
patients of COPD [6,7]. It comprises 8 questions, each
presented as a semantic 6-point (0–5) differential scale,
providing a total score out of 40. Scores of 0–10, 11–20,
21–30, 31–40 represent mild, moderate, severe or very se-
vere clinical impact, respectively [8]. Evidence has shown
its good internal consistency and test-retest reliability
[7,9], and it is suitable for routine clinical use for both
stable and exacerbating COPD [10-13]. Currently, the
CAT has been translated into many languages and used
worldwide, including China [14], but as yet no data is
available on whether the CAT can be used to assess the re-
sponse to treatments at exacerbations or therapeutic inter-
ventions in China.
COPD exacerbations usually accompanied with in-
creased airway and systemic inflammation [15,16]. The
dynamic changes of systemic inflammatory biomarkers
following exacerbations can be used to evaluate the thera-
peutics efficacy [5]. An obvious symptom recovery and
reduction in systemic inflammation can be seen in seven
days following a positive treatment [15]. In this study, we
hypothesize that the CAT scores following exacerbations
are correlated with the systemic inflammation (evaluated
by CRP and fibrinogen), mMRC grades, as well as the pul-
monary function. Therefore, we propose that the CAT
may be a potentially useful instrument to evaluate the
therapeutic response to exacerbation treatments.
Methods
Subjects
The study involved patients with clinician-diagnosed
COPD exacerbation, which defined as an acute event
characterized by a worsening of respiratory symptoms
(dyspnea, sputum purulence or sputum volume) that is
beyond normal day-to-day variations and leads to a changein medication [2,17]. Subjects were recruited from the
Pulmonary Department, First Affiliated Hospital of Anhui
Medical University from August 2012 to January 2013.
Patients with an established history of COPD were in-
cluded, with a post-bronchodilator forced expiratory vo-
lume in one second (FEV1) to forced vital capacity (FVC)
ratio <70% at diagnosis [2], in addition, they should be able
to understand and complete the CAT, SGRQ and mMRC
dyspnea scale independently. Exclusion criteria were as
follows: Patients with a primary diagnosis of asthma,
bronchiectasis or other active chronic respiratory disease
requiring treatments, interventions or diagnostics, or any
other severe or uncontrolled comorbidities; Patients with
mental disorders or any other condition associated with
an immuno-inflammatory response; Patients who had re-
ceived antibiotic or corticosteroids during the past four
weeks were also excluded. The study was approved by the
ethics committee of First Affiliated Hospital of Anhui
Medical University. All patients provided written consent
to participate and were informed the possible risks of the
study. Patients were screened according to the strategies
illustrated in Figure 1.
Patients were recruited on the day they presented with
an acute exacerbation. Demographic information, de-
tailed medical and smoking history were record at re-
cruitment. The exacerbation frequency, which was based
on the number of exacerbations the patient recalled for
the year prior to recruitment was also collected. Pre-
vious studies have shown a good correlation between
exacerbation frequency recorded on diary cards and that
remembered by the patient over the same one year
period [18].Measurement of systemic inflammatory biomarkers and
arterial blood gas analysis
Prior to treatments, peripheral venous blood samples of
all subjects were taken to test the concentrations of serum
CRP and plasma fibrinogen, which measured by the
Modular Analytics E170 Module (Roche, Burgess Hill,
UK) and the Claus method (IL ACL Top Coagulation
Analyzer, Lexington, MA ,USA) respectively, the arterial
oxygen (PaO2) and carbon dioxide tensions (PaCO2) were
evaluated with a Stat Profile Critical Care Xpress (Nova
Biomedical, Waltham, Mass, USA) while patients breathed
room air in the supine position. After 7 days’ therapy, all
subjects were required to take another venous blood sam-
ple to measure serum CRP and plasma fibrinogen follo-
wing the methods mentioned above.Health-related quality of life questionnaires and mMRC
dyspnea scale
Patients completed the CAT and SGRQ questionnaires
and mMRC dyspnea scale independently at exacerbation
Figure 1 Strategies for screening patients with AECOPD.
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was measured by the CAT score.Pulmonary function test
Standardized pulmonary function test was performed
both at exacerbation and the 7th day of therapy with a
dry spirometer device (Erich Jaeger GmbH, Hoechberg,
Germany) at 15 minutes after inhaling salbutamol 400 μg
(Ventolin; GlaxoSmithKline; London, UK), and the FVC,
FEV1, and FEV1/FVC ratio were recorded.
Patients at exacerbation were treated according to the
prevailing guidelines and clinical judgment with inhaled
short-acting β2-agonists, antibiotics, systemic corticoste-
roids and theophylline, etc. [2]. Neither the magnitude of
the exacerbation CAT/SGRQ score nor the mMRC grades
played any role in the treatment decisions. On the 7th day
of therapy, the patients were required to have a statement
on the global rating changes in COPD since the first day
independently, with a six-point single-item classifying
change as ‘much worse’, ‘worse’, ‘no change’, ‘better’, ‘much
better’, or ‘completely resolved’ referred to the method
Jones and his colleagues had used [12]. Responders were
defined as having a global rating of change ‘better’, ‘much
better’, or ‘completely resolved’. Non-responders weredefined as having a global rating of change ‘no change’,
‘worse’, or ‘much worse’.Statistical analysis
Demographic and clinical characteristics of patients were
summarized descriptively. Data were expressed as mean ±
standard deviation. Skewed distribution data were made
to normal distribution data by ㏒10 transformation. SPSS
Statistics version 17.0 was used for statistical analysis. The
Pearson regression was used to analyze the correlations
between CAT scores and inflammatory biomarkers, SGRQ
scores, FEV1% predicted, the correlations between the
mMRC grades and CAT scores, inflammatory biomarkers
were analyzed by analysis of variance (ANOVA). Group
comparisons were tested using t-tests or Chi-Square test.
A P value <0.05 was considered significant in all statistical
analyses.Results
Patient characteristics
A total of 130 AECOPD patients were screened and 78
patients were eligible. Their baseline characteristics are re-
ported in Table 1, alongside the subgroup of 39 patients
who also performed the pulmonary function test on the
Table 1 Demographic characteristics of the total and
subgroup patients
Variable Total group Sub group P value
(n = 78) (n = 39)
Age, years 69.01 ± 10.39 67.90 ± 11.02 0.56a
Females, n (%) 34(43.58) 18(46.15) 0.78b
BMI, kg/m2 21.82 ± 4.02 21.06 ± 3.87 0.89a
Smoking status, %
Current smoker 35.14 40.93 0.66b
Ex-smoker 35.12 33.26
Never smoked 29.74 25.81
Smoking index,
pack-years
43.00 ± 26.00 41.00 ± 23.00 0.67a
Comorbidities, n (%) 33(49.25) 18(46.15) 0.69b
Exacerbation frequency 2.55 ± 1.44 2.58 ± 1.62 0.92a
Education, years 6.79 ± 5.17 6.51 ± 4.89 0.63a
PaO2, mm Hg 67.05 ± 18.90 67.80 ± 23.40 0.54a
PaCO2, mm Hg 44.48 ± 11.85 43.42 ± 15.08 0.31a
Pulmonary function
at exacerbation
FEV1, % predicted 46.79 ± 19.14 45.37 ± 20.27 0.71a
FEV1, L 0.90 ± 0.33 0.82 ± 0.38 0.39a
FVC, L 1.57 ± 0.56 1.49 ± 0.57 0.44a
Data are presented as mean ± standard deviation, except where indicated
otherwise. Comorbidities included hypertension, diabetes mellitus, cerebral
infarction, coronary artery disease, and these comorbidities were all in stable
state which confirmed by physicians from related departments. BMI = Body
Mass Index. at-test. bχ2 test.
Table 2 CRP, fibrinogen, CAT and SGRQ scores, mMRC
grades before and after therapy (n = 78)
Exacerbation The 7th day P value
㏒10CRP, mg/ L 1.14 ± 0.69 0.39 ± 0.52 <0.001
㏒10fibrinogen, g/ L 0.59 ± 0.16 0.37 ± 0.16 <0.001
SGRQ 55.17 ± 17.07 41.69 ± 16.48 <0.001
CAT 23.19 ± 7.00 12.83 ± 5.82 <0.001
mMRC grades 2.73 ± 0.99 1.36 ± 0.91 <0.001
Data are presented as mean ± standard deviation, P value was calculated by
paired t-test.
CRP = C-reactive protein, CAT = COPD Assessment Test, SGRQ = St George’s
Respiratory Questionnaire.
Table 3 Relationships between CAT, SGRQ scores and
CRP, fibrinogen (n = 78)
Exacerbation The 7th day
r P value r P value
CAT vs ㏒10CRP 0.398 <0.001 0.409 <0.001
CAT vs ㏒10fibrinogen 0.392 <0.001 0.262 <0.05
SGRQ vs ㏒10CRP 0.282 <0.05 0.354 0.001
SGRQ vs ㏒10fibrinogen 0.292 0.01 0.297 <0.01
CRP = C-reactive protein, CAT = COPD Assessment Test, SGRQ = St George’s
Respiratory Questionnaire. r = Pearson Correlation coefficient.
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line characteristics (P > 0.05). After 7 days’ therapy, 76
patients were responders and only 2 patients were non-
responders, the mean change in CAT score of the 78
patients was (−10.36 ± 5.03) units, among which the
“responders” was (−10.49 ± 4.83) units and the “non-
responders” was −0.93 units (the mean value of the two
patients).
The relationships between the CAT, SGRQ, mMRC and
inflammatory biomarkers
After ㏒10 transformation, the concentrations of CRP and
fibrinogen were not affected by exacerbation frequency,
comorbidities, or smoking status (P > 0.05). After 7 days’
therapy, the CAT and SGRQ scores, mMRC grades, as well
as the concentrations of CRP and fibrinogen all had a sig-
nificantly reduction (P < 0.001), as shown in Table 2. The
CAT and SGRQ scores at exacerbation and the 7th day of
therapy were all significantly related to concurrent levels of
CRP and fibrinogen as shown in Table 3. The mean change
in CAT score (−10.36 ± 5.03 units) following exacerbation
was significantly related to the change in CRP (r = 0.286,
P < 0.05), but not in fibrinogen (r = 0.137, P > 0.05), as shown
in Figure 2. No relationship was found between the changesof SGRQ score (−13.47 ± 8.98 units) and CRP or fibrinogen
(P > 0.05). Positive correlations were found between the
mMRC grades and concurrent levels of CRP (exacerbation:
rs = 0.256, P < 0.05, the 7th day of therapy: rs = 0.289,
P = 0.01) and fibrinogen (exacerbation: rs = 0.296, P < 0.01,
the 7th day of therapy: rs = 0.246, P < 0.05). The mean
change of CRP (1.04 ± 0.79 mg/L) was positively related to
that of fibrinogen (0.12 ± 0.38 g/L, r = 0.485, P < 0.001).
The CAT and exacerbation frequency
The mean CAT scores of the 78 patients at exacerbation
and the 7th day after of therapy were 23.19 ± 7.00 and
12.83 ± 5.82, respectively, Patients with frequent exacer-
bations (≥2 exacerbations during the past year, n = 60)
had a significantly higher mean exacerbation CAT score
of 24.74 ± 7.21 compared to infrequent exacerbations
(<2 exacerbations during the past year, n = 18) with a
mean exacerbation CAT score of 20.62 ± 5.75 (P < 0.001).
After 7 days’ therapy, frequent exacerbators still had a
higher CAT score of 15.35 ± 6.00 than infrequent exacer-
bators with a CAT score of 10.62 ± 4.66 (P < 0.005). The
mean exacerbation frequency was 2.55 ± 1.44 times du-
ring the past one year.
The CAT and SGRQ, mMRC
The CAT scores were positively correlated with concur-
rent SGRQ scores (exacerbation r = 0.831, the 7th day of
therapy r = 0.774, both P < 0.001) and mMRC grades (ex-
acerbation rs = 0.832, the 7th day of therapy rs = 0.786,
Figure 2 Pearson correlations between the change in CAT score
and the changes of inflammatory biomarkers. ● solid line =Δ㏒10
CRP vs ΔCAT: r = 0.286, P < 0.05;▲ dash line =Δ㏒10 fibrinogen vs
ΔCAT: r = 0.137, P > 0.05. Δ= the change of CAT scores and the
concentrations of CRP and fibrinogen.
Figure 3 Box plots of CAT scores in patients grouped mMRC
grades at exacerbation (Figure 3A) and the 7th day of therapy
(Figure 3B). The horizontal line through each box represents the
median. The ends of each box represent the 25th and 75th
percentile locations, and the lines represent the range of the date.
The cross of each box represents the mean.
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significantly related to that of SGRQ score (r = 0.725,
P < 0.001) and mMRC grades (rs = 0.593, P < 0.001). The
effect on quality of life according to the CAT scores and
the mMRC grades of the total subjects was shown in
Table 4. Figure 3 showed the distribution of the CAT
scores grouped by the mMRC grades at exacerbation and
the 7th day of therapy.
The CAT and pulmonary function
A subgroup of 39 patients performed the pulmonary
function test both at exacerbation and the 7th day of
therapy. Significant improvement was found in FEV1%
predicted on the 7th day of therapy (P < 0.001), as the
mean value at exacerbation and the 7th day after therapyTable 4 CAT stages and mMRC grades before and after
therapy (n = 78)
Exacerbation The 7th day P value












P value was calculated byχ2 test.was (45.37 ± 20.27) % and (48.80 ± 19.84) %, respectively.
Significantly negative correlations were found between the
CAT scores and contemporaneous FEV1% predicted (ex-
acerbation r = −0.683, the 7th day after therapy r = −0.591,
both P < 0.001, Figure 4), but no correlation was found
between the changes of CAT score and FEV1% predicted
(r = −0.101, P > 0.05).
No difference in CAT score was found between smokers
and non-smokers, as well as in patients with comorbidities
or without comorbidities (P>0.05).
Discussion
This study, to our knowledge, is the first time to use the
CAT to assess the treatment response and health status
following exacerbations of COPD in China. Results have
shown that the CAT and SGRQ scores, mMRC grades
and the concentrations of CRP and fibrinogen during
exacerbation all decreased significantly after 7 days’
Figure 4 Pearson correlations between CAT scores and FEV1%
predicted. ● solid line = Exacerbation: r = −0.683;▲ dash line = the
7th day after therapy: r = −0.591, both P < 0.001.
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cant improvement. The CAT scores were significantly
correlated with concurrent levels of CRP and fibrinogen,
mMRC grades, SGRQ scores and FEV1% predicted. The
change in CAT score was related to that of CRP, SGRQ
score and mMRC grades. Furthermore, we have shown
that the CAT scores were significantly higher in patients
with a history of frequent exacerbations.
COPD is associated with increased systemic inflamma-
tion [19,20], and the inflammation is aggravated during
exacerbations [15,16]. Recent advances using inflam-
matory biomarkers suggest that quantification of serum
proteins are effective in the diagnosis, classification, prog-
nosis, and treatment response of COPD [5,21]. Both CRP
and fibrinogen are acute-phase inflammatory biomarkers
that are normally used in clinic, their concentrations will
generally rise in response to infections but decline with
the clinical recovery [22,23]. In this study, we found most
patients had much higher concentrations of CRP and
fibrinogen at exacerbation, probably triggered by bacte-
rial and/or viral infections [24,25]. With the symptoms
recovered, both CRP and fibrinogen had a significant re-
duction corresponding to the decrease of systemic inflam-
mation, reflecting an effective treatment during the seven
days. Our results showed that moderate but significan
correlations (r = 0.262 to 0.409) were found between the
levels of CRP and fibrinogen and concurrent CAT scores,
SGRQ scores, and mMRC grades, these are reasonable as
the clinical symptoms and poor health status in COPD
patients are caused by a great many factors including the
systemic inflammation [2,26]. Meanwhile, the inflam-
matory response may lag behind clinical and biochemical
response following AECOPD [27], which can partly ac-
counts for the weak correlations between inflammatory
mediators and CAT/SGRQ scores. No relationship wasfound between the changes of SGRQ scores and CRP or
fibrinogen after 7 days’ therapy. We speculate this attri-
butes to the relatively weaker correlations between the
SGRQ scores and CRP and fibrinogen following exacerba-
tions as compared with the CAT scores, thus suggesting
the CAT is more sensitive to the inflammatory response
following exacerbations. More studies, probably of longi-
tudinal nature will be required to test and verify these
associations.
With the simplicity and reliability of CAT, it is now re-
commended to assess the symptom burden and health
status of COPD patients [2]. The SGRQ is a disease-
specific measure of health status for COPD. In the present
study, significantly positive correlations were found be-
tween the CAT and SGRQ scores both at exacerbation
and the 7th day of therapy, which was consistent with the
initial validated studies [7]. Previous studies have shown
that the relationship between the CAT and SGRQ is con-
stant across the scaling range [28], and the mathematical
relationship is CAT = 0.4 × SGRQ. However, what is inter-
esting in our study is that the CAT score (12.83 ± 5.82
units) seems very small compared to SGRQ (41.69 ± 16.48
units) on the 7th day of therapy. We believe that the dif-
ference may be caused by the higher sensitivity of CAT to
the clinical response of treatments following exacerbations
than that of SGRQ. Mackay et al. have demonstrated that
the CAT can provide a score of COPD exacerbation se-
verity and model recovery following exacerbations [13].
Furthermore, the CAT is responsive to pulmonary re-
habilitation and can distinguish different levels of response
[29,30]. Our study complements the existing work by
demonstrating that the CAT is an objective measurement
to assess the treatment response following COPD exacer-
bations. This has particular relevance as the CAT provides
an additional tool to assess the ability of novel interven-
tions to reduce exacerbation severity and make compa-
risons across studies easier. However, we found that the
mean change in CAT score over the 7 days in our study
was quite dramatic (−10.36 ± 5.03 units) compared to pre-
vious studies [12,13]. We speculate there are two main
factors, one is that most patients in the present study
came from the countryside and they received less formal
treatment in stable state, which made them are more sen-
sitive and effective to the treatments when compared with
those who had received the guidelines recommended
treatments; Meanwhile, these patients were in low eco-
nomic state and had more serious symptoms when hospi-
talized at exacerbations of COPD.
Dyspnea is the most prominent and distressing symp-
tom of COPD patients. With the disease progresses, the
severity of dyspnea and the frequency of exacerbations
also increased, leading to a reduction in patients’ daily
activities and health-related quality of life. In the present
study, the CAT scores were positively correlated with
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with studies conducted by Zhou and Jones [31,32]. Both
CAT and mMRC Dyspnea Scale were recommended to
assess the symptom burden of COPD patients in the re-
vised global strategy [2]. Considering dyspnea is not the
only symptom that affects health status, and the CAT has
a broader coverage of the impact of COPD on the patient’s
daily life and well-being. Therefore, it is more appropriate
to use the CAT as a symptom burden and heath status
measurement. COPD patients are accompanied with per-
sistent airflow limitation. Exacerbations can accelerate the
decline of lung function and often with an incomplete
symptomatic or physiological resolution [33], thus leading
to reduced physical activities and poorer quality of life. In
our study, the CAT scores were significantly and modestly
related to contemporaneous lung function impairment
(measured by FEV1% predicted), in accordance with pre-
vious data [13]. However, we found that the change in
CAT score was not related to that of FEV1% predicted,
probably due to the recovery of physiological function lags
behind the symptoms recovery. Exacerbation frequency is
associated with the health status impairment of COPD
patients [34]. Our study demonstrated that frequent
exacerbators have higher CAT scores than infrequent
exacerbators during exacerbations, which is expected be-
cause the CAT scores in stable COPD patients with a his-
tory of frequent exacerbations are significantly higher than
infrequent ones [13].
There are some limitations in our study. Firstly, the in-
formation in stable state of the subjects (basal CAT and
SGRQ scores, pulmonary function parameters and mMRC
grades, etc.) were absent, thus lacking the comparisons
between stable state and exacerbation and recovery. Se-
condly, this study has the relatively small size of the par-
ticipant population, especially the subjects who performed
the spirometry on the 7th day of therapy. The small sam-
ple size may leads to the weak correlations between some
measurements in our results, as well as some mild differ-
ence between our results and previous studies.
Conclusions
In conclusion, the CAT is associate with the changes of
systemic inflammation following exacerbations, and it is
as responsive to the treatments as other measures such
as SGRQ, mMRC dyspnea scale and pulmonary func-
tion. Thus the CAT scores can reflect the health status
of COPD patients, and are potentially useful to assess
the treatments response following COPD exacerbations.
In addition, the CAT is particular useful for health set-
tings where access to other objective measurements is
limited.
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